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Osteoporosis is a major age-related source of
morbidity and mortality. Increased bone re-
sorption mediated by osteoclasts is central
to its pathogenesis. Cytokines, particularly
RANKL and TNFa, are often increased under
pathologic conditions, leading to enhanced
osteoclastogenesis. Black cohosh (Actaea/
Cimicifuga racemosa L), a popular herbal sup-
plement for the treatment of menopausal symp-
toms, was recently shown to have the beneficial
effect of preventing bone loss. Here, we dem-
onstrate that 25-acetylcimigenol xylopyrano-
side (ACCX), a triterpenoid glycoside isolated
from black cohosh, potently blocks in vitro os-
teoclastogenesis induced by either RANKL or
TNFa. This blockage of osteoclastogenesis eli-
cited by ACCX results from abrogation of the
NF-kB and ERK pathways induced by either
RANKL or TNFa, respectively. Importantly, this
compound attenuates TNFa-induced bone
loss in vivo. Therefore, ACCX represents a po-
tential lead for the development of a new class
of antiosteoporosis agents.
INTRODUCTION
Osteoporosis is a major age-related heath problem that is
characterized by decreased bone density and increased
risk of fractures. It is especially common in woman after
menopause and is initiated by estrogen deficiency. The
underlying pathogenesis of reduced bone mass in osteo-
porosis is an imbalance of osteoclast-mediated bone re-
sorption relative to osteoblast-mediated bone formation,
resulting in a net loss of bone [1–4].
Although postmenopausal osteoporosis is epidemic,
the choices of treatments are far from ideal. Although860 Chemistry & Biology 14, 860–869, July 2007 ª2007 Elsevierestrogen-replacement therapy can prevent postmeno-
pausal osteoporosis [5, 6], it increases the risk for breast
cancer, stroke, heart attack, and blood clots, and it is no
longer used for long-term treatment [7, 8]. Drugs that
either block osteoclast resorption, such as bisphospho-
nates, or increase bone formation, such as PTH, are
proposed as alternatives. Bisphosphonates, however,
are poorly absorbed from the gastrointestinal (GI) tract
and have been associated with GI adverse events [9];
whereas, PTH, a therapeutic peptide, cannot be given
orally, and concern about osteosarcoma has led to a rec-
ommendation of a 2 year maximum treatment course [10].
Therefore, the search for other alternative treatment
options is of considerable scientific and public interest.
Natural products (NPs) havebeenasuccessful sourceof
therapeutic agents anddrug leads. The roots and rhizomes
of black cohosh have a long history ofmedicinal use by na-
tive North Americans for treatment of gynecological disor-
ders and rheumatism [11]. In the past several decades, nu-
traceutical products made from an alcoholic extract of the
roots and rhizomes of black cohosh extract have been
used primarily as dietary supplements for the treatment
of hot flashes, profuse sweating, nervous irritability, and
other menopausal symptoms in the United States and Eu-
rope. Several randomized clinical trials document positive
effects of black cohosh extract on menopausal symptoms
[12–14]. Interestingly, animal studies with the rat ovariec-
tomymodel of osteoporosis suggest that extracts of black
cohosh exhibit protective effects on estrogen-deficiency-
induced bone loss [15, 16]. The mechanism of action of
black cohosh on bone cells and the responsible active
components, however, remain elusive.
Despite considerable efforts in seeking plant-derived
estrogen-like substances, namely, phytoestrogens, in
black cohosh, growing evidence suggests that this plant
does not possess phytoestrogens [13, 16–21]. Therefore,
black cohosh may confer its bone loss-protection effects
through a novel mechanism rather than the estrogenic
pathway. The accumulated phytochemical studies reveal
that black cohosh contains structurally diversified cyclo-
artane triterpene glycosides and aromatic acids as theLtd All rights reserved
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terpene glycosides have cytotoxicity or antiproliferation
activity against cancer cells [25–29] and aromatic acids
have antioxidant activity [30], none of them has been in-
vestigated for their effects on bone cells. Thus, identifica-
tion of the active component for the protective effects of
black cohosh on bone loss and the delineation of the mo-
lecular mechanism of action merit further investigation.
Osteoclasts play a central role in pathological bone
loss, including postmenopausal osteoporosis [3, 4]. Loss
of estrogen markedly increases the generation, function,
and lifespan of osteoclasts [3, 4]. Despite a variety of
mechanisms through which estrogen deficiency induces
bone loss, upregulation of the osteoclastogenic cytokines
RANKL and TNFa plays a significant role [31, 32]. The pos-
itive effects of black cohosh extract on bone loss promp-
ted us to investigate the hypothesis that the bioactive
components of black cohosh directly target osteoclasts
to prevent bone loss.
Here, we report that 25-acetylcimigenol xylopyranoside
(ACCX), a cycloartane triterpenoid glycoside isolated from
black cohosh, potently blocks osteoclastogenesis in-
duced by either RANKL or TNFa, with inhibition of the
NF-kB and ERK pathways. Importantly, the efficacy of
this compound on attenuation of TNFa-induced bone
loss is verified in vivo. Because RANKL and TNFa are im-
portant mediators of bone loss in several pathological
conditions, including inflammatory osteolysis and post-
menopausal osteoporosis, ACCX represents a promising
therapeutic agent.
RESULTS
ACCX Dampens Osteoclastogenesis In Vitro
Initially, all of the 46 compounds that we isolated from
black cohosh were screened to evaluate their effects on
in vitro osteoclastogenesis. Bone marrow macrophages
(BMMs) were induced to generate osteoclasts in cell
culture plates by the addition of M-CSF and RANKL in
the presence or absence of the tested compounds at
100 mM. Compounds that showed inhibition of osteoclas-
togenesis were tested again at concentrations ranging
from 5 to 50 mM. Among the compounds tested, ACCX
(Figure 1A) is the most potent inhibitor of osteoclastogen-
esis, with an IC50 of 5 mM (Figure 1B), followed by cimi-
genol, actein, and cimiaceroside B, with IC50 values of 25,
42, and 45 mM, respectively, while others showed no activ-
ity (IC50 > 100 mM). Therefore, we chose ACCX for further
investigation. This compound is one of the major compo-
nents of black cohosh and comprises about 0.1%–0.5%
of an ethanolic extract of black cohosh. ACCX significantly
impairs osteoclast formation in a dose-dependent fashion
(Figure 1B). The blockage of osteoclastogenesis by ACCX
is not due to potential toxicity of this compound because
cells preexposed to ACCX for 24 hr exhibit a normal
capacity to generate osteoclasts after removal of this
compound (Figure 1B).
To determine at which stage ACCX inhibits osteoclasto-
genesis, ACCX was added to osteoclast differentiationChemistry & Biology 14,cultures beginning at days 0–4. This compound potently
inhibited osteoclastogenesis when added during the first
2 days, while exposure of precursor cells to ACCX at later
stages was not effective in the prevention of osteoclasto-
genesis (Figure 1C). Since the precursors exposed to
RANKL for 3 days have already committed to osteoclast
differentiation, it is reasonable to suggest that ACCX
blocks osteoclast differentiation but cannot reverse the
differentiation process once cells have committed to the
osteoclast lineage.
Effects of ACCX on Proliferation and Cell Death
of BMMs
Data presented thus far establish that ACCXblocks osteo-
clastogenesis. Given that impaired osteoclastogenesis in
the presence of ACCX may reflect decreased proliferation
or elevated cell death of the precursor cells, we next
examined the effects of ACCX on proliferation and cell
death of BMMs. ACCX at 10 mM, which completely blocks
osteoclastogenesis, only caused moderate inhibition of
proliferation in the presence of M-CSF alone or with
RANKL, although greater inhibition can be induced when
higher doses of ACCX are used (Figure 2A). Furthermore,
despite the fact that higher doses elicited cell death,
ACCX induced no or minimal cell death at doses up to
10 mM (Figure 2B).
ACCX Alters RANKL-Induced Signaling Events
Osteoclast differentiation from BMMs is induced by
RANKL, whereas M-CSF promotes proliferation of osteo-
clast precursors and survival of osteoclasts and their pre-
cursors [1, 2, 33]. Upon binding to its receptor RANK,
RANKL rapidly activates the NF-kB pathway via activating
IKK, which phosphorylates IkBa and targets it for protea-
somal degradation and leads to translocation of NF-kB
from the cytosol to the nucleus to bind its target sequence
and activate transcription of the NF-kB target genes [1, 2].
Simultaneously, RANKL activates MAPKs, including ERK,
p38, and JNK [1, 2]. More distally, RANKL upregulates the
only known osteoclastogenic transcription factor, NFAT2,
and a number of osteoclast-specific proteins, such as
Cathepsin K, b3 integrin, and c-Src.
To test whether ACCX blocks osteoclastogenesis via
altering RANKL signals, we examined the effects of
ACCX on these downstream events. ACCX blocks
RANKL-induced phosphorylation and degradation of
IkBa, indicating inhibition of the NF-kB pathway (Fig-
ure 3A). Furthermore, the blockage of IkBa degradation
by ACCX is dose and time dependent (Figures 3B and
3C). Moreover, NF-kB DNA-binding activity is also in-
hibited by ACCX (Figure 3D), providing further support
that ACCX inhibits the NF-kB pathway. RANKL-induced
phosphorylation of ERK is also inhibited by ACCX
(Figure 3E). On the other hand, p38 activation is prolonged
(Figure 3E). Additionally, the peak of JNK activation is
blunted, although the basal level of activation is moder-
ately increased (Figure 3E). Consistent with impaired
osteoclastogenesis in the presence of ACCX, this com-
pound eliminates expression of NFAT2, Cathepsin K,860–869, July 2007 ª2007 Elsevier Ltd All rights reserved 861
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(A) Structure of ACCX.
(B andC) BMMswere grown in the presence of 10 ng/mlM-CSF and 100 ng/ml RANKL for 4 days to generatemature osteoclasts. ACCXwas supplied
to the medium at the indicated concentration for (B) 4 days (upper panels), for (B) 1 day at the beginning before being withdrawn for the remaining
3 days (lower panels), or (C) at 10 mM at the indicated time. Cells were stained for TRAP.and b3 integrin and reduces expression of c-Src (Fig-
ure 3F), providing further evidence that osteoclast differ-
entiation is arrested by ACCX.
TNFa-Induced In Vitro Osteoclastogenesis
Is Blocked by ACCX
TNFa is the critical inflammatory cytokine that leads to in-
flammation-induced osteoclastogenesis and bone loss
[34–36]. This cytokine is upregulated in estrogen-deficient
mice and is essential for the bone loss induced by estro-
gen deficiency [32, 37]. Addition of ACCX at 10 mM com-
pletely blocks osteoclast differentiation induced by TNFa
(Figure 4A).
To gain insights into how ACCX dampens TNFa-
induced osteoclastogenesis, we examined the effects of
ACCX on TNFa-induced activation of the NF-kB pathway
andMAPKs, including ERK, p38, and JNK. Similar to its ef-
fects on RANKL signaling, ACCX inhibits TNFa-induced
activation of ERK, while it constitutively activates p38862 Chemistry & Biology 14, 860–869, July 2007 ª2007 Elsevieand JNK, blunts peak JNK activation, and prolongs p38
phosphorylation (Figure 4B). Furthermore, this compound
blocks phosphorylation and degradation of IkBa induced
by TNFa (Figure 4C). Given that activated NF-kB
stimulates the transcription of a number of target genes,
including TNFa, IkBa, and TLR2, we examined whether
inhibition of the NF-kB pathway by ACCX leads to
downregulation of these genes. Indeed, ACCX did prevent
both RANKL- and TNFa-induced transcription of endoge-
nous TNFa, IkBa, and TLR2, as revealed by RT-PCR anal-
ysis (Figure 4D).
ACCX Reduces In Vivo Osteoclastogenesis
and Bone Resorption Induced by TNFa
To evaluate the effects of ACCX on osteoclastogenesis in
vivo, we injected mice daily with TNFa and ACCX or its
solvent DMSO for 5 days. Given that ACCX is not water
soluble and that DMSO-dissolved ACCX can form precip-
itates when diluted in water at more than 200 mM, wer Ltd All rights reserved
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of ACCX in vivo. Mice not injected or injected with
DMSO alone were used as controls for basal levels of
osteoclastogenesis. DMSO alone did not impact osteo-
clastogenesis (Figures 5A and 5B). TNFa increased osteo-
clastogenesis (Figures 5A and 5B) irrespective of ACCX.
The extent of osteoclastogenesis induced by TNFa, how-
ever, was significantly reduced in the mice injected with
ACCX (Figures 5A and 5B).
DISCUSSION
Osteoclasts play a key role in menopausal osteoporosis.
Estrogen deficiency enhances the genesis and activity of
osteoclasts, resulting in an unbalanced increase in bone
resorption [2–4]. Recent studies have established that
black cohosh, a widely used herbal medicine to alleviate
menopausal symptoms, reduces bone loss in the ovariec-
tomized rat model [15, 16]. These observations prompted
us to investigate whether a component of black cohosh is
capable of blocking osteoclastogenesis. We established
that a triterpenoid glycoside, ACCX, inhibits osteoclasto-
genesis induced by RANKL in a dose-dependent manner.
Figure 2. Effects of ACCX on Proliferation and Cell Death of
BMMs
(A) BMMs were grown in the presence of 10 ng/ml M-CSF with or with-
out 100 ng/ml RANKL for 24 hr. Cells were simultaneously exposed to
ACCX at the indicated concentrations. Cells were labeledwith BrdU for
6 hr and were then assayed for BrdU incorporation (*p < 0.01 versus
nontreated).
(B) BMMs were cultured with 10 ng/ml M-CSF and were exposed to
ACCX at the indicated concentration for 24 hr. DNA fragmentation
was assayed by cell death ELISA (*p < 0.05, **p < 0.0005 versus non-
treated; the error bars show standard deviations).Chemistry & Biology 14,This compound only showsmoderate inhibition of prolifer-
ation, and induction of cell death elicited by this com-
pound occurs at doses that completely eliminate osteo-
clastogenesis. Most importantly, ACCX directly targets
differentiation of osteoclasts from their precursors, as
demonstrated by the fact that ACCX-treated cells com-
pletely lack osteoclast-specific marker proteins, such as
Cathepsin K and b3 integrin.
Osteoclastogenesis is induced by RANKL under physi-
ological conditions [1, 2]. Although the exact mechanism
by which RANKL induces osteoclastogenesis is not com-
pletely understood, it is known that RANKL-induced
activation of the NF-kB and MAPK pathways as well as
upregulation of NFAT2 expression are required for osteo-
clastogenesis [38–41]. We find that ACCX eliminates
RANKL-induced activation of the NF-kB pathway, as
demonstrated by a lack of phosphorylation and degrada-
tion of IkBa, an absence of NF-kB DNA-binding activity,
and an absence of RANKL-induced expression of the
NF-kB-dependent genes. Although the exact targets of
ACCX on the NF-kB pathway remain to be determined,
our data suggest that the potential targets are upstream
of IkBa phosphorylation. The importance of the NF-kB
pathway in osteoclastogenesis is underscored by the
findings that mice lacking both NF-kB p50 and p52 or
mice deficient in IKKb postnatally are osteopetrotic [42–
44]. Furthermore, peptide inhibitors of IKK are effective
in preventing osteoclastogenesis and bone loss in
a mouse model of arthritis [45, 46]. Therefore, it is reason-
able to suggest that inhibition of the NF-kB pathway is
likely responsible for ACCX-elicited blockage of osteo-
clastogenesis.
RANKL-induced activation of MAPKs is also modulated
by ACCX. This triterpene dampens RANKL-induced acti-
vation of ERK. Given the positive role of ERK activation
in cell proliferation [47], ACCX-elicited inhibition of ERK
activation is likely responsible for the reduced proliferation
of osteoclast precursors in the presence of the com-
pound. RANKL also transiently activates JNK and p38,
which is important for osteoclastogenesis [1, 2]. ACCX
does not block these pathways. Instead, ACCX activates
p38 in the absence of RANKL and prolongs p38 activation.
On the other hand, ACCX at an effective dose for blocking
osteoclastogenesis only increases basal activation of
JNK, while attenuating peak activation of JNK. High doses
of ACCX prolong JNK activation (data not shown). A num-
ber of studies suggest that prolonged activation of JNK
leads to cell death, whereas transient activation of JNK
leads to proliferation [48–50]. The observation that ACCX
potently increases cell death at high doses is in agreement
with the notion that constitutive activation of JNK leads to
cell death.
TNFa is the primary inflammatory cytokine responsible
for bone loss occurring in various pathological conditions
[51]. The finding that TNFa-deficient mice are protected
from estrogen-deficiency-induced bone loss establishes
the critical role of TNFa in this circumstance as well [32].
TNFa stimulates osteoclastogenesis indirectly via in-
creased expression of M-CSF, IL-1, and RANKL in860–869, July 2007 ª2007 Elsevier Ltd All rights reserved 863
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(A) BMMswere grown in serum-freemedium for 6 hrwith orwithout exposure to 10mMACCX for 4 hr.Cellswere subsequently stimulatedwith 100ng/ml
RANKL for the indicated time periods. Cell lysates were subjected to immunoblotting with antibodies as indicated.
(B) BMMs were treated in a manner similar to that described in (A), but with indicated doses of ACCX, and were stimulated with RANKL for 15 min.
(C) BMMs were treated with 20 mM ACCX for the indicated time periods and were stimulated with RANKL for 15 min.
(D) Cells were treatedwith or without 20 mMACCX for 4 hr, followed by RANKL (100 ng/ml) stimulation for 0 or 30min. Nuclear extracts were allowed to
bind biotin-labeled oligonucleotides bearing a kB site. Bound proteins were pulled down with streptavidin beads and were immunoblotted with a
p65 antibody. Nucleophosmin in nuclear extracts served as an input control.
(E) Similar to (A).
(F)BMMswereculturedwith20ng/mlM-CSFand100ng/mlRANKLwithorwithout 10mMACCX.Cell lysateswerecollectedat the indicated timeperiods
and were subjected to immunoblotting with antibodies as indicated.stromal/osteoblast cells, while it also directly facilitates
osteoclast differentiation from BMMs primed with RANKL
[36, 52–54]. We found that ACCX blocks TNFa-induced
osteoclastogenesis in vitro. Similar to the effect on RANKL
signaling, ACCX eliminates TNFa-induced activation of
the NF-kB and the ERK pathways while leading to pro-
longed activation of p38 and increased basal activation
of JNK. Most importantly, ACCX reduces TNFa-induced
osteoclastogenesis in vivo.
Our study clearly establishes that a component of black
cohosh, ACCX, directly targets osteoclastogenesis from
BMMs. Our data, however, do not exclude the possibility
that other mechanisms or other less potent components
from black cohosh may also contribute synergistically to
the beneficial skeletal effects of this natural product. In
fact, we find that the constituent cimigenol is also active
in the blockage of osteoclastogenesis, although it is
much less potent than ACCX. Interestingly, the structure
of cimigenol is very similar to that of ACCX (without the
acetyl group and sugar in cimigenol), whereas other ana-
logs, cimigenol xylopyranoside (CX, missing the 25-acetyl
group with respect to ACCX) and 25-acetylcimigenol (AC,864 Chemistry & Biology 14, 860–869, July 2007 ª2007 Elseviewithout the xylose with respect to ACCX), are inactive, re-
vealing subtle yet strict requirements for optimal activity.
On the other hand, black cohosh extracts were shown to
stimulate production of the decoy receptor for RANKL,
osteoprotegrin (OPG), in osteoblasts and, therefore, to
indirectly impair osteoclastogenesis [55]. The responsive
component of black cohosh responsible for upregulation
of OPG, however, remains to be determined.
SIGNIFICANCE
Black cohosh is one of themost popular dietary botan-
icals for treatment of menopausal symptoms. An alco-
holic extract of this herb shows the beneficial effect of
preventing bone loss in vivo. Themechanism of action
and the responsible active component, however, need
to be identified. The current discovery is significant in
several respects. First, to our knowledge, ACCX is the
first component in black cohosh that is proven to ex-
hibit potent inhibition of osteoclastogenesis both
in vitro and in vivo, providing a scientific rationale at
the molecular level for the claim that black cohoshr Ltd All rights reserved
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osteoporosis/bone loss. Second, ACCX is a novel
inhibitor of the NF-kB pathway, representing a New
Chemical Entity (NCE) targeting NF-kB pathways.
This compound also targets theMAPK pathway. Mod-
ulating multiple targets may provide better therapeu-
tic intervention to alleviate menopausal osteoporosis
and other inflammatory bone erosion, rendering
ACCX as a chemical tool for studies of osteoporosis
biology and as a potential lead for the development
of a new class of antiosteoporosis agents.
Figure 4. ACCX Blocks TNFa-Induced Osteoclastogenesis
in Vitro and Alters TNFa- Elicited Signaling Events
(A) BMMs were cultured with 50 ng/ml M-CSF and 50 ng/ml TNFawith
or without 10 mM ACCX for 5 days. Cells were stained for TRAP.
(B and C) BMMs were grown in serum-free medium with or without ex-
posure to 10 mM ACCX for 4 hr. Cells were stimulated with 50 ng/ml
TNFa for the indicated time periods. Cell lysates were analyzed by im-
munoblotting with indicated antibodies.
(D) BMMs pretreated with or without 10 mM ACCX for 4 hr were stim-
ulated with 200 ng/ml RANKL or 50 ng/ml TNFa for 30 min. Levels of
TNFa, IkBa, and TLR2 mRNA were determined by RT-PCR. GAPDH
mRNA served as loading controls.Chemistry & Biology 14,EXPERIMENTAL PROCEDURES
Reagents and Antibodies
Antibodies for phospho-IkBa, phospho-JNK, JNK, p38, phospho-p38,
ERK, phospho-ERK, and b3 were purchased from Cell Signaling Tech-
nology. Antibodies for p65, NFAT2, IkBa, and Cathepsin K were
obtained from Santa Cruz Biotechnology, Inc. The anti-b-actin anti-
body was obtained from Sigma-Aldrich. The antibody for nucleophos-
min was obtained from J. Weber (Washington University, St. Louis,
MO). The monoclonal antibody for c-Src was a gift of Dr. A. Shaw
(Washington University, St. Louis, MO). Recombinant human M-CSF
was generously provided by Dr. D.H. Fremont (Washington University,
St. Louis, MO). Murine recombinant GST-RANKL was previously
described [56].
Isolation of Triterpenoid Glycosides from Black Cohosh
and Structure Confirmation of ACCX
The pooled ethanolic extracts of the rhizomes of Cimicifuga racemosa
(10 kg, purchased from Indiana Botanical Garden, Hobert, IN) were
concentrated under vacuum until most of the organic solvents were re-
moved. The residue (1 kg) was suspended in warm water (4 l, 60C)
and then partitioned successively with petroleum ether, ethyl acetate,
and n-BuOH (4 l 3 4 each). The ethyl acetate extract (500 g) was sub-
jected to column chromatography on silica gel (2 kg, 160–200 mesh)
and eluted with petroleum ether-acetone (5:1–1:1) to give four frac-
tions. Each fraction was further separated by using alternatively nor-
mal-phase and reverse-phase Chromatorex C18 silica gel chromatog-
raphy to afford 46 compounds, including 32 triterpenoid glycosides,
6 aromatic acids, and 8 others whose structures were determined by
using a combination of mass spectroscopy and 1D- and 2D-NMR
techniques. ESI mass spectra were recorded with a Thermo-Finnigan
LCQDECA spectrometer (see the Supplemental Data available with this
article online). NMR spectra were obtained with a Bruker Avance 600
spectrometer. The physical and spectral data of ACCX ([23R, 24S]
25-O-acetyl-cimigenol-3-O-b-D-xylopyranoside) are as follows: color-
less needles, mp 240–242C, ½a20D : +38 (c 0.1044, MeOH); ESI-MS
m/z: 685 [M+Na]+, 661 [MH]; Molecular formula C37H58O10. 1H-NMR
(600 MHz, pyridine-d5) d: 3.49 (1H, d, J = 11.3 Hz, 3a-H), 4.23 (1H, s,
15b-H), 1.11 (3H, s, 18-Me), 0.26, 0.50 (each 1H, d, J = 2.6 Hz, 19-H),
0.83 (3H, d, J = 9.4 Hz, 21-Me), 4.56 (1H, d, J = 9.2 Hz, 23-H), 4.08
(1H, s, 24-H), 1.93 (3H, s, 25-OAc), 1.65 (3H, s, 26-Me), 1.63 (3H, s,
27-Me), 1.16 (3H, s, 28-Me), 1.30 (3H, s, 29-Me), 1.03 (3H, s, 30-Me),
4.83 (1H, d, J = 7.1 Hz, 10-H), 4.01(1H, t, J = 8.1 Hz, 20-H), 4.12 (1H,
t, J = 8.5 Hz, 30-H), 4.19 (1H, dd, J = 8.3, 4.1 Hz, 40-H), 3.70 (1H, t,
J = 10.9 Hz, 50-H), 4.32 (1H, dd, J = 4.9, 10.7 Hz, 50-H); 13C-NMR
(150 MHz, pyridine-d5) d: 32.4 (C-1), 30.9 (C-2), 88.5 (C-3), 41.3 (C-4),
47.2 (C-5), 21.0 (C-6), 26.3 (C-7), 48.6 (C-8), 20.0 (C-9), 26.4 (C-10),
26.7 (C-11), 34.0 (C-12), 41.8 (C-13), 47.6 (C-14), 80.1 (C-15), 112.4
(C-16), 59.4 (C-17), 19.5 (C-18), 30.9 (C-19), 23.9 (C-20), 19.5 (C-21),
37.9 (C-22), 71.7 (C-23), 86.7 (C-24), 83.1 (C-25), 22.2 (C-26), 23.4
(C-27), 11.8 (C-28), 25.7 (C-29), 15.4 (C-30), 170.1(-COCH3), 21.5
(-COCH3) (the corresponding chemical shift is denoted by the under-
lined carbon), 107.5 (C-10), 75.5 (C-20), 78.6 (C-30 ), 71.2 (C-40), 67.1
(C-50). The identity of ACCX and other compounds was achieved
by establishing that their NMR data are nearly identical with those re-
ported in the literature [11, 22–24].
Cell Culture
Whole bonemarrow cells were isolated from flushing the long bones of
4- to 8-week-old C57BL/6 mice (Jackson Laboratory). These cells
were grown in a-MEM with 10% FBS and 1:10 CMG14-12 culture su-
pernatant [57] containing 1.2 mg/ml M-CSF for 3 days to generate bone
marrow macrophages (BMMs). To generate osteoclasts, 50 ng/ml
M-CSF and 100 ng/ml RANKL or 50 ng/ml TNFa were added to
a-MEM medium containing 10% FBS. Osteoclasts were stained for
tartrate-resistant acid phosphatase (TRAP) as per the manufacturer’s
instructions (Sigma-Aldrich).860–869, July 2007 ª2007 Elsevier Ltd All rights reserved 865
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Induced by TNFa Is Reduced by ACCX
Mice were injected daily with DMSO or ACCX
with or without supracalvaria injection of
TNFa for 5 days and were sacrificed the follow-
ing day.
(A) Histological sections of calvaria from these
mice were stained for TRAP activity.
(B) Histomorphometric quantitation of the
percentage of bone surface covered by os-
teoclasts in calvaria of each group of mice
(*p < 0.005, **p < 0.02, versus DMSO; #p <
0.04, versus TNFa + DMSO; the error bars
show standard deviations).Western Blot Analysis
Cultured cells were washed twice with ice-cold PBS and were lysed in
a buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate,
1 mM b-glycerophosphate, 1 mM Na3VO4, 1 mM NaF, and 13 prote-
ase inhibitor mixture. Cell lysates were clarified by centrifugation at
6000 rpm for 5 min. Western blot analysis was carried out by using
20–40 mg total proteins as previously described [54].
Proliferation Assay and Cell Death ELISA Assay
BMMs were plated in 96-well plates at 1 3104 cells/well and were
grown for 1 day. Cells were labeled with BrdU for the last 6 hr of culture.
The BrdU ELISA assay was carried out as recommended by using the
cell proliferation biotrak ELISA system (Amersham Biosciences). Cell
death was analyzed by using the cell death detection ELISAPLUS kit
(Roche Applied Science) as per the manufacturer’s instructions. Qua-
druplicate samples were used. All experiments were repeated with
satisfactory results.
RT-PCR
RNA was isolated by using RNeasy kits (QIAGEN Sciences). First-
strand cDNA was generated from 1 mg total RNA by using the Super-
Script First-Strand Synthesis System for RT-PCR (Invitrogen) as
recommended by the manufacturer. One fifth of the RT reaction prod-
uct, 45 ml PCR SuperMix (Invitrogen), and 0.5 mMprimers for the genes
to be tested were amplified in a PCR Express Thermal Cycler
(HYBAID). The cDNA was denatured at 94C for 5 min and was sub-866 Chemistry & Biology 14, 860–869, July 2007 ª2007 Elseviesequently subjected to various amplification cycles comprised of
94C for 40 s, 60C for 50 s, and 72C for 60 s. The primers (listed in
the 50 to 30 direction) used were as follows: (1) TNFa, AATGGCCTC
CCTCTCATCAGTTCT and TGAGATAGCAAATCGGCTGACGGT; (2)
IkBa, CAAGTGGAGTGGAG TCTGCAGGTTGTT and GCCTGGACTC
CATGAAGGAC; (3) TLR2, GGCTTCCTCTTGGCCTGGAG and GGA
GACTCTGGAAGCAGGCG; (4) GAPDH, ACTTTGTCAAGCTCATTTCC
and TGCAGCGAACTTTATTGATG.
NF-kB DNA-Binding Assay
BMMs were treated with or without 20 mM ACCX for 4 hr, followed by
RANKL (100 ng/ml) stimulation for 0 or 30 min. Cells were collected
in hypotonic buffer (10 mM HEPES [pH 7.6], 1.5 mM MgCl2, 1 mM
KCl, 5 mMNaF, 1 mMNa3VO4, 1 mMDTT, 13 protease inhibitor cock-
tail [Roche Applied Science]) and were lyzed by the addition of NP-40
(0.1%). After centrifugation at 10,000 3 g for 30 s at 4C, nuclear
pellets were washed with hypotonic buffer, collected again by centri-
fugation, and resuspended in high-salt buffer (400 mM NaCl in hypo-
tonic buffer). Biotin-labeled oligonucleotides for NF-kB-binding sites
[58] were purchased from Invitrogen and were conjugated to strepta-
vidin agrose beads (Sigma). A total of 20 mg nuclear proteins were
mixed with 10 ml agarose beads in binding buffer (30 mM NaCl,
10 mM Tris [pH 7.4], 1 mM EDTA, 5% glycerol, 1 mg/ml BSA, 1 mM
DTT, 13 protease inhibitor cocktail) in the presence of 1 mg poly
dIdC (Pharmacia) for 45min at room temperature. Beads were washed
three timeswith binding buffer and resuspended in SDS-PAGE loadingr Ltd All rights reserved
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Triterpene from Black Cohosh Inhibits Osteoclastsbuffer (Cell Signaling). Proteins were analyzed by immunoblotting with
p65 antibody.
TNFa-Induced In Vivo Osteoclastogenesis and Histological
Analysis
C57BL/6 mice (6 weeks old) were purchased from the Jackson Labo-
ratory and were housed in the animal care unit at Washington Univer-
sity School of Medicine. Mice were intraperitoneally injected daily with
50 ml DMSO or ACCX dissolved in DMSO (12 mg/kg/mouse) with or
without supracalvaria injection of TNFa (3 mg in PBS/mouse) for
5 days. Each group had 5–10 mice. All animals were sacrificed on
day 6. Calvaria taken from these mice were sequentially fixed in 10%
buffered formalin for 24 hr, decalcified in 14% EDTA (pH 7.2) for
7 days, dehydrated in graded alcohol, cleared through xylene, and em-
bedded in paraffin. Paraffin sections were stained histochemically for
TRAP. Histomorphometric quantitation was performed by using the
Bioquant System (BIOQANT Image Analysis). All animal experiments
were approved by the Animal Studies Committee of Washington
University School of Medicine.
Supplemental Data
Supplemental Data include structures of compounds 25-acetylcimige-
nol xylopyranoside (ACCX), cimigenol xylopyranoside (CX), cimigenol
(C), acetylcimigenol (AC), actein, and cimiaceroside B, as well as
NMR data of ACCX, and are available at http://www.chembiol.com/
cgi/content/full/14/7/860/DC1/.
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